KR102776570B1 - 인지 기능을 향상시키기 위한 H3K9me3 조절의 용도 - Google Patents

인지 기능을 향상시키기 위한 H3K9me3 조절의 용도 Download PDF

Info

Publication number
KR102776570B1
KR102776570B1 KR1020187000444A KR20187000444A KR102776570B1 KR 102776570 B1 KR102776570 B1 KR 102776570B1 KR 1020187000444 A KR1020187000444 A KR 1020187000444A KR 20187000444 A KR20187000444 A KR 20187000444A KR 102776570 B1 KR102776570 B1 KR 102776570B1
Authority
KR
South Korea
Prior art keywords
substituted
unsubstituted
delete delete
compound
etp69
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187000444A
Other languages
English (en)
Korean (ko)
Other versions
KR20180014432A (ko
Inventor
칼 코트만
래리 오버맨
시카 스니그다
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 filed Critical 더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Publication of KR20180014432A publication Critical patent/KR20180014432A/ko
Application granted granted Critical
Publication of KR102776570B1 publication Critical patent/KR102776570B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/548—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/18—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Amplifiers (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Networks Using Active Elements (AREA)
KR1020187000444A 2015-06-08 2016-06-03 인지 기능을 향상시키기 위한 H3K9me3 조절의 용도 Active KR102776570B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562172690P 2015-06-08 2015-06-08
US62/172,690 2015-06-08
PCT/US2016/035764 WO2016200690A1 (en) 2015-06-08 2016-06-03 USE OF H3K9me3 MODULATION FOR ENHANCING COGNITIVE FUNCTION

Publications (2)

Publication Number Publication Date
KR20180014432A KR20180014432A (ko) 2018-02-08
KR102776570B1 true KR102776570B1 (ko) 2025-03-04

Family

ID=57504356

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187000444A Active KR102776570B1 (ko) 2015-06-08 2016-06-03 인지 기능을 향상시키기 위한 H3K9me3 조절의 용도

Country Status (11)

Country Link
US (5) US10272093B2 (https=)
EP (2) EP3303347B1 (https=)
JP (1) JP6851081B2 (https=)
KR (1) KR102776570B1 (https=)
CN (1) CN107849061B (https=)
AU (2) AU2016276172B2 (https=)
CA (1) CA2988568A1 (https=)
ES (2) ES2807878T3 (https=)
IL (1) IL256055B (https=)
MX (1) MX2017015909A (https=)
WO (1) WO2016200690A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2807878T3 (es) * 2015-06-08 2021-02-24 Univ California Uso de la modulación de H3K9me3 para potenciar la función cognitiva
WO2018234367A1 (en) * 2017-06-20 2018-12-27 Institut Curie SUV39H1 HISTONE METHYLTRANSFERASE INHIBITOR FOR USE IN ANTICANCER POLYTHERAPY
CN108434454B (zh) * 2018-03-16 2019-10-11 大连医科大学 Adar1在缓解认知功能障碍方面的应用
WO2020223475A1 (en) * 2019-05-02 2020-11-05 Board Of Regents, The University Of Texas System Methods and compositions involving tert activating therapies
AU2021320639A1 (en) * 2020-08-03 2023-03-30 Cedars-Sinai Medical Center Compositions and methods for treating alzheimer's disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120101147A1 (en) 2008-12-03 2012-04-26 The General Hospital Corporation D/B/A Massachusetts General Hospital Inhibition of hdac2 to promote memory
WO2015081166A1 (en) 2013-11-26 2015-06-04 University Of North Texas Health Science Center At Fort Worth Personalized medicine approach for treating cognitive loss

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534255B1 (en) 2003-01-24 2009-05-19 Photothera, Inc Low level light therapy for enhancement of neurologic function
US20060019227A1 (en) * 2004-07-22 2006-01-26 Hardwicke Susan B Methods for cognitive treatment
WO2006084033A1 (en) * 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
CN101466365A (zh) * 2006-06-09 2009-06-24 惠氏公司 增强认知功能的方法
JP2009084271A (ja) * 2007-09-07 2009-04-23 Toyama Univ 脳由来神経栄養因子の発現誘導剤および発現誘導方法
ES2662332T3 (es) * 2010-03-04 2018-04-06 Merck Sharp & Dohme Corp. Inhibidores de la catecol-O-metil-transferasa y su uso en el tratamiento de trastornos psicóticos
KR101235256B1 (ko) * 2010-09-13 2013-02-21 서울대학교산학협력단 ｍｉＲＮＡ를 타겟으로 한 신경퇴행성 질환 치료
JP6465803B2 (ja) * 2012-10-22 2019-02-06 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ｅｔｐ誘導体
CA2909506C (en) * 2013-04-17 2021-04-20 H. Lundbeck A/S Nalmefene for treatment of patients with anxiety disorder
ES2807878T3 (es) * 2015-06-08 2021-02-24 Univ California Uso de la modulación de H3K9me3 para potenciar la función cognitiva

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120101147A1 (en) 2008-12-03 2012-04-26 The General Hospital Corporation D/B/A Massachusetts General Hospital Inhibition of hdac2 to promote memory
WO2015081166A1 (en) 2013-11-26 2015-06-04 University Of North Texas Health Science Center At Fort Worth Personalized medicine approach for treating cognitive loss

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Journal of Cerebral Blood Flow & Metabolism, 2015, Vol. 35, pp. 1640-1647 (doi:10.1038/jcbfm.2015.99)*

Also Published As

Publication number Publication date
MX2017015909A (es) 2018-05-07
EP3303347A1 (en) 2018-04-11
US11311551B2 (en) 2022-04-26
US20180228808A1 (en) 2018-08-16
ES2944446T3 (es) 2023-06-21
US20230057592A1 (en) 2023-02-23
JP2018516940A (ja) 2018-06-28
KR20180014432A (ko) 2018-02-08
ES2807878T3 (es) 2021-02-24
AU2019246902B2 (en) 2021-08-19
US20240374608A1 (en) 2024-11-14
US20190209577A1 (en) 2019-07-11
CA2988568A1 (en) 2016-12-15
CN107849061B (zh) 2021-05-14
EP3733188A1 (en) 2020-11-04
EP3733188B1 (en) 2023-01-25
AU2016276172A1 (en) 2018-01-04
AU2016276172B2 (en) 2019-07-11
EP3303347B1 (en) 2020-05-06
JP6851081B2 (ja) 2021-03-31
US10272093B2 (en) 2019-04-30
CN107849061A (zh) 2018-03-27
IL256055B (en) 2022-06-01
EP3303347A4 (en) 2019-03-06
AU2019246902A1 (en) 2019-10-31
IL256055A (en) 2018-01-31
WO2016200690A1 (en) 2016-12-15
US20210106590A1 (en) 2021-04-15
US10849910B2 (en) 2020-12-01

Similar Documents

Publication Publication Date Title
US20240374608A1 (en) USE OF H3K9me3 MODULATION FOR ENHANCING COGNITIVE FUNCTION
Snigdha et al. H3K9me3 inhibition improves memory, promotes spine formation, and increases BDNF levels in the aged hippocampus
Rogawski AMPA receptors as a molecular target in epilepsy therapy
Li et al. Zerumbone ameliorates behavioral impairments and neuropathology in transgenic APP/PS1 mice by suppressing MAPK signaling
Xu et al. Role of autophagy in sevoflurane-induced neurotoxicity in neonatal rat hippocampal cells
CA3050700C (en) Use of pridopidine for the treatment of fragile x syndrome
Zhang et al. Atorvastatin prevents amyloid-β peptide oligomer-induced synaptotoxicity and memory dysfunction in rats through a p38 MAPK-dependent pathway
Hu et al. Pathological mechanisms of amyotrophic lateral sclerosis
Di Prisco et al. Presynaptic, release‐regulating mGlu2‐preferring and mGlu3‐preferring autoreceptors in CNS: pharmacological profiles and functional roles in demyelinating disease
Liu et al. Inhibiting 5-hydroxytryptamine receptor 3 alleviates pathological changes of a mouse model of Alzheimer’s disease
Ma et al. A novel phthalein component ameliorates neuroinflammation and cognitive dysfunction by suppressing the CXCL12/CXCR4 axis in rats with vascular dementia
Wang et al. Chrysin alleviates lipopolysaccharide-induced neuron damage and behavioral deficits in mice through inhibition of Fyn
HK40040355A (en) Use of h3k9me3 modulation for enhancing cognitive function
HK40040355B (en) Use of h3k9me3 modulation for enhancing cognitive function
Zhou et al. Valproic acid inhibits neurosphere formation by adult subventricular cells by a lithium-sensitive mechanism
Shelton The Effects of Two Novel Anti-Inflammatory Compounds on Prepulse Inhibition and Neural Microglia Cell Activation in a Rodent Model of Schizophrenia
Ma et al. Fetal Growth Restriction Mice Are More Likely to Exhibit Depression-Like Behaviors Due to Stress-Induced Loss of Dopamine Neurons in the VTA
HK40016661A (en) Pridopidine for use in the treatment of fragile x syndrome
HK40016661B (en) Pridopidine for use in the treatment of fragile x syndrome
Qiu Maresin-1 attenuates LPS-induced depressive-like behavior in adolescent mice and promotes M2 microglial polarization via ERK/NF-κB signaling

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180105

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210601

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240314

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241202

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250227

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250227

End annual number: 3

Start annual number: 1

PG1601 Publication of registration